<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02342158</url>
  </required_header>
  <id_info>
    <org_study_id>PERMED01-IPC 2014-003</org_study_id>
    <nct_id>NCT02342158</nct_id>
  </id_info>
  <brief_title>Identifying Molecular Alterations to Guide Individualized Treatment in Advanced Solid Tumors</brief_title>
  <acronym>PERMED01</acronym>
  <official_title>Identifying Molecular Alterations to Guide Individualized Treatment in Advanced Solid Tumors-PERMED01-IPC 2014-003</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Institut Paoli-Calmettes</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Cancer Research Center of Marseille</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Institut Paoli-Calmettes</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      PERMED01 is a prospective monocenter clinical trial which aims to evaluate the number&#xD;
      patients with locally advanced or metastatic cancer for whom identification of molecular&#xD;
      alterations in tumor samples can lead to the delivery of a targeted therapy. PERMED01 will&#xD;
      enroll 460 patients in 3 years.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">November 12, 2014</start_date>
  <completion_date type="Anticipated">November 2022</completion_date>
  <primary_completion_date type="Actual">June 2020</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Other</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>proportion of screened patients in whom a molecular abnormality for which a targeted therapy exists</measure>
    <time_frame>4-6 weeks after biopsy</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Molecular Characterization of locally advanced and metastatic malignancies using next generation sequencing</measure>
    <time_frame>3.5 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Full exome and transcriptome sequencingof locally advanced and metastatic tumours</measure>
    <time_frame>6 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Circulating tumor DNA detection and characterization in locally advanced and metastatic disease</measure>
    <time_frame>4 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Circulating Tumor Cells (CTC) detection and characterization in breast cancer</measure>
    <time_frame>3.5 years</time_frame>
    <description>Comparison of three distinct methods for the CTC detection in blood</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Preclinical predictive clinical models validation (limited to breast cancer)</measure>
    <time_frame>4 years</time_frame>
    <description>Patient-derived tumour xenograft models (PDX), drug sensitivity tests in vitro</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">550</enrollment>
  <condition>Neoplasm Metastasis</condition>
  <arm_group>
    <arm_group_label>Locally advanced /metastatic cancer</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>biopsy or surgical sampling</intervention_name>
    <arm_group_label>Locally advanced /metastatic cancer</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>blood sampling</intervention_name>
    <arm_group_label>Locally advanced /metastatic cancer</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Age&gt;18 years&#xD;
&#xD;
          -  Histological diagnosis of cancer&#xD;
&#xD;
          -  Locally advanced or metastatic, biopsiable disease&#xD;
&#xD;
          -  ECOG Performans Status â‰¤2&#xD;
&#xD;
          -  Affiliation to social security&#xD;
&#xD;
          -  Signed informed consent.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Emergency, Individually deprived of liberty or placed under the authority of a tutor&#xD;
&#xD;
          -  Patients with symptomatic or progressive brain metastasis&#xD;
&#xD;
          -  Patients who have only bone and/or brain metastases&#xD;
&#xD;
          -  Pregnant or breastfeeding women&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Institut Paoli-Calmettes</name>
      <address>
        <city>Marseille</city>
        <zip>13009</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>January 2021</verification_date>
  <study_first_submitted>December 16, 2014</study_first_submitted>
  <study_first_submitted_qc>January 14, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 19, 2015</study_first_posted>
  <last_update_submitted>January 21, 2021</last_update_submitted>
  <last_update_submitted_qc>January 21, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">January 22, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neoplasm Metastasis</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

